What the screen needs to hear

Start with the reason for the visit

It's fine to arrive curious about semaglutide. We would put the reason next to the name: what are you hoping treatment might change, and what worries you about it? That gives the conversation somewhere useful to go.

The research doesn't cover one interchangeable group. The STEP 1 weight trial studied adults with obesity, or overweight plus a weight-related condition, without diabetes. A clinician needs your history to work out how evidence like that fits your situation.

Bring the everyday details

A list of current medicines and supplements is a useful start. Past reactions and relevant diagnoses belong beside it. The concern that doesn't fit neatly into a checkbox is worth writing down too.

The Wegovy (semaglutide) label flags a personal or family history of medullary thyroid carcinoma, a rare thyroid cancer. It also rules out use with multiple endocrine neoplasia type 2, or MEN 2, a rare inherited condition. Pancreas, gallbladder, stomach and diabetic eye problems are other topics in the label.

Pregnancy plans, other diabetes medicines and an upcoming procedure under anesthesia also matter. This isn't a way to check your own eligibility. It's a way to make the history easier to discuss.

Can the conversation go both ways?

An intake form can start the exchange. The important question is whether someone can follow up when an answer needs more detail.

The Federation of State Medical Boards' telemedicine model policy rejects treatment based solely on a fixed questionnaire that cannot support an adequate assessment. Its prescribing guidance also says patients must be able to ask their own follow-up questions. These are documents for medical boards; each state's enforceable rules still matter.

We'd ask who reviews the information, how questions reach them and what happens if the assessment raises something the form can't resolve. A submitted form can leave plenty still to discuss.

Some answers need a test or an examination

The same model policy calls for clinicians to arrange needed tests or refer for in-person assessment. Remote care doesn't make missing information disappear. Sometimes the next useful step happens away from the screen.

A practical question is what a proposed test is meant to clarify. Another is who reviews the result and explains any change to the plan. Those answers make a referral easier to understand.

Before the call ends

We'd want the exact product name in plain words. Are we discussing an approved product, or a compounded medicine? Compounded medicines are not FDA-approved, even when the ingredient name is familiar.

Then there's the next contact: who handles a new symptom, an unclear instruction or a treatment change? Our effects notes and follow-up page can help frame those questions. A useful appointment can end with more assessment or a decision to wait.